ReviewReviews in endocrine & metabolic disorders2017
Management of neuroendocrine tumors of unknown primary.
Review in Reviews in endocrine & metabolic disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- A new, machine learning-based approach to metastatic neuroendocrine tumors of unknown origin.Journal of neuroendocrinology · 2026Article
- DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms.Nature communications · 2025Article
- Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44-ALK Fusion: A Case Report and Literature Review.The clinical respiratory journal · 2024Review
- Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy.Annals of surgical oncology · 2024Article
- A Neuroendocrine Tumor of Unknown Primary Origin: A Case Report and Review of the Literature.Cureus · 2024Article
- Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia.Endocrine · 2023Article
- Article
- Multidisciplinary Approach to the Diagnosis of Occult Primary Neuroendocrine Neoplasm: A Clinical Challenge.Journal of clinical medicine · 2023Review
- Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms.Diagnostics (Basel, Switzerland) · 2023Review
- Small bowel neuroendocrine neoplasm: what surgeons want to know.Abdominal radiology (New York) · 2022Review
- An abdominal wall neuroendocrine tumor of unknown primary origin: A case report and review of the literature.Cancer reports (Hoboken, N.J.) · 2022Review
- Cushing's syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review.Hormones (Athens, Greece) · 2022Review
- Thoracic dumbbell spinal metastasis secondary to neuroendocrine tumor of unknown origin: Case report and literature review.Surgical neurology international · 2022Article
- Management Impact ofNuclear medicine and molecular imaging · 2021Article
- Methionyl-tRNA synthetase and aminoacyl-tRNA synthetases interacting multi-functional protein-lacking exon 2 as potential diagnostic biomarkers for lung cancer.American journal of cancer research · 2021Article
- PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2020Article
- The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.Endocrine · 2019Article
- Metastatic Insulinoma Presenting as a Liver Cyst.Journal of pathology and translational medicine · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplams (NENs) are mostly relatively indolent malignancies but a significant number have metastatic disease at diagnosis mainly to the liver. Although in the majority of such cases the primary origin of the tumor can be identified, in approximately 11-22% no primary tumor is found and such cases are designated as NENs of unknown primary origin (UPO). This has significant therapeutic implications with respect to potentially resectable hepatic disease and/or application of appropriate medical therapy, either chemotherapeutic agents or targeted treatment, as the response to various treatments varies according to the origin of the primary tumor. This lack of tumor specific orientated treatment may also account for the relatively poorer prognosis of NENs of UPO compared to metastatic NENs with a known primary site. In the majority of cases the primary tumors are located in the small bowel and the lung, but a number may still elude detection. Occasionally the presence of a functional syndrome may direct to the specific tissue of origin but in the majority of cases a number of biochemical, imaging, histopathological and molecular modalities are utilized to help identify the primary origin of the tumor and direct treatment accordingly. Several diagnostic algorithms have recently been developed to help localize an occult primary tumor; however, in a number of cases no lesion is identified even after prolonged follow-up. It is expected that the delineation of the molecular signature of the different NENs may help identify such cases and provide appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.